Adma Biologics (ADMA) Operating Expenses (2011 - 2025)

Adma Biologics' Operating Expenses history runs 13 years deep, the most recent figure standing at $26.1 million for Q4 2025.

• Quarterly Operating Expenses rose 4.22% year-over-year to $26.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $101.3 million (up 25.76% YoY) and the FY2025 annual result came in at $101.3 million, up 25.76% from the prior year.
• Operating Expenses was $26.1 million for Q4 2025 at Adma Biologics, up from $24.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $26.2 million in Q1 2025 and bottomed at $13.4 million in Q1 2021.
• A 5-year average of $19.2 million and a median of $17.8 million in 2023 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 155.46% in 2021, while the deepest fall reached 50.16% in 2021.
• Adma Biologics' Operating Expenses stood at $16.7 million in 2021, then increased by 21.15% to $20.2 million in 2022, then declined by 16.72% to $16.9 million in 2023, then soared by 48.4% to $25.0 million in 2024, then rose by 4.22% to $26.1 million in 2025.
• Business Quant data shows ADMA's Operating Expenses at $26.1 million in Q4 2025, $24.6 million in Q3 2025, and $24.4 million in Q2 2025.